BioNTech (NasdaqGS:BNTX) has started five additional pivotal oncology trials in collaboration with Bristol Myers Squibb. The company has expanded its oncology pipeline with new candidates entering ...
BioNTech (NASDAQ:BNTX) has been analyzed by 12 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below provides a concise overview of ...
BioNTech (BNTX) stock was under pressure on May 5 after the multinational announced plans to eliminate up to 1,860 roles as ...
The company reaffirmed its full-year 2026 revenue guidance of $2.3 to $2.6 billion and maintained a strong cash position of ...
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. BioNTech (NasdaqGS:BNTX) cofounders Ugur Sahin and Özlem ...
BioNTech is quite undervalued after you back out a tremendous and growing cash hoard garnered from its COVID vaccine windfall. The company's mRNA technology and other therapies in development could ...
BioNTech will close manufacturing sites in Germany and Singapore, cutting up to 1,860 jobs as it shifts focus from COVID-19 vaccines to oncology. The closures, tied to overcapacity and cost-cutting, ...
In the last three months, 4 analysts have published ratings on BioNTech (NASDAQ:BNTX), offering a diverse range of perspectives from bullish to bearish. In the table below, you'll find a summary of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results